Roivant maintained its 19.5% stake by proportionately tendering, signaling no change in its long-term commitment to Arbutus. Monitor for any future strategic initiatives or board representation discussions given Roivant's significant ownership.
Price Chart
Executive Summary
Roivant Sciences Ltd. filed Amendment No. 14 to its Schedule 13D on Arbutus Biopharma Corp, reporting beneficial ownership of 29,880,079 common shares (19.5%) following a proportionate tender in Arbutus's modified Dutch auction tender offer. Roivant tendered 8,967,383 shares at $5.00 per share for aggregate consideration of approximately $44.8 million, maintaining its proportional ownership after the company repurchased 46 million shares for $230 million.
Key Financial Metrics
Key Facts
- Roivant beneficially owns 29,880,079 common shares, or approximately 19.5% of Arbutus's outstanding shares.
- Arbutus completed a modified Dutch auction tender offer to purchase up to $230 million of its common shares at $5.00-$5.75 per share.
- The offer expired on September 29, 2026; Arbutus accepted 46,000,000 shares at $5.00 per share.
- Roivant made a proportionate tender of 8,967,383 shares, receiving approximately $44.8 million in proceeds.
- Roivant's ownership percentage remained unchanged at 19.5% after the tender offer.
- No new activist demands or changes in purpose were disclosed in this amendment.
Financial Impact
Roivant received approximately $44.8 million from tendering 8,967,383 shares at $5.00 per share in Arbutus's $230 million tender offer.
Risk Factors
- Roivant's large stake (19.5%) could lead to future activist pressure or strategic demands.
- The tender offer reduced Arbutus's share count by 46 million shares, potentially increasing earnings per share but also reducing cash reserves by $230 million.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13D/A Filing (Primary) | 0001140361-26-038693 |
| Document: 0001140361-26-038693-index-headers.html | 0001140361-26-038693 |
| Document: 0001140361-26-038693-index.html | 0001140361-26-038693 |
| Document: 0001140361-26-038693.txt | 0001140361-26-038693 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | 8-K | $4.21 | awaiting T+60 | — | $4.20 (−0.24%) |
Oct 22, 2026 4d ago | Press Release | $4.21 | awaiting T+60 | — | $4.20 (−0.24%) |
Oct 7, 2026 19d ago | SC 13G/A | $4.18 | awaiting T+60 | — | $4.20 (+0.48%) |
Oct 5, 2026 20d ago | SC 13D/A | $4.48 | awaiting T+60 | — | $4.20 (−6.25%) |
Oct 1, 2026 25d ago | SC TO-I/A | $4.56 | awaiting T+60 | — | $4.20 (−7.89%) |
Oct 1, 2026 25d ago | Press Release | $4.56 | awaiting T+60 | — | $4.20 (−7.89%) |
Sep 30, 2026 26d ago | SC TO-I/A | $4.78 | awaiting T+60 | — | $4.20 (−12.13%) |
Sep 30, 2026 26d ago | Press Release | $4.78 | awaiting T+60 | — | $4.20 (−12.13%) |
Aug 21, 2026 9w ago | 8-K | $5.21 | awaiting T+60 | — | $4.20 (−19.39%) |
Aug 15, 2026 10w ago | Institutional Cluster | $4.71 | awaiting T+60 | — | $4.20 (−10.83%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers